Physician profile
Michael J Ulich
NPI 1629161773
$1,423.12
in general payments reported to CMS, 2019-2025
12 companies · $319 in 2025
The $319 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $47.08 · 2021: $29.36 · 2022: $163 · 2023: $430 · 2024: $222 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $409.26 | 2022-2024 | Azstarys |
| Tris Pharma INC | $280.28 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $196.37 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $125.00 | 2025 | Jornay Pm |
| Pfizer INC. | $124.47 | 2019 | |
| Supernus Pharmaceuticals, INC. | $88.44 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $62.58 | 2020-2022 | |
| Sanofi Pasteur INC. | $45.26 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $41.29 | 2022-2024 | Vaqta, Vaxelis, Gardasil |
| Astrazeneca Pharmaceuticals LP | $21.65 | 2024 | Flumist Quadrivalent |
| Shire North American Group INC | $16.36 | 2019 | |
| Aytu Biopharma, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ulich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.